Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04977180 | Cardioprotection in AML(AML 001) | recruiting | Phase 2 | 70 | University of VirginiaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07374029 | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | recruiting | Phase 1 | 30 | David AviganOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04482894 | Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | active not recruiting | N/A | 105 | University of VirginiaOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07563920 | TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission(TBF-AML) | not yet recruiting | N/A | 93 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT07564453 | Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia(FLOW) | recruiting | Phase 2 | 101 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05833438 | Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy(VENAZA-5S) | active not recruiting | Phase 2 | 45 | University of LeipzigOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07551037 | Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy(AML) | recruiting | Phase 1 | 90 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07561892 | Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).(AML) | recruiting | Phase 4 | 100 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563179 | Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | recruiting | Phase 2 / Phase 3 | 316 | Taiho Oncology, Inc.INDUSTRY | 10 | Apr 30, 2026 | clinicaltrials |
| NCT05366569 | Bio-CAR-T BS Study | recruiting | — | 45 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06497062 | Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 47 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07420790 | Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial(VenDec-AI) | recruiting | — | 1,941 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07559695 | A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT | recruiting | — | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06195891 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07048535 | CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions | recruiting | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07278882 | Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL | recruiting | N/A | 100 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07499765 | Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis(ANX-LA) | recruiting | N/A | 110 | Centre Henri BecquerelOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | active not recruiting | Phase 1 | 37 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01627041 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 2 | 178 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03178617 | High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma | active not recruiting | N/A | 214 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05396859 | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 20 | Benjamin TomlinsonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06735690 | Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552649 | Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia(MATCH-Treg) | not yet recruiting | Phase 2 | 28 | Antonio PieriniOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03164057 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 206 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05428969 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies(BEXMAB) | active not recruiting | Phase 1 / Phase 2 | 181 | Faron Pharmaceuticals LtdINDUSTRY | 3 | Apr 23, 2026 | clinicaltrials |
| NCT05550948 | Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer | active not recruiting | N/A | 44 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06074666 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3 | recruiting | N/A | 100 | Roswell Park Cancer InstituteOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia | recruiting | Phase 2 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05101551 | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy(PARPAML) | recruiting | Phase 1 | 34 | Norman J. LacayoOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06599762 | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia(MYELO-CAN:TXA) | recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07320235 | Imetelstat Combinations in Relapsed AML(IMAGINE) | recruiting | Phase 1 | 36 | Douglas TremblayOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03188874 | Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) | recruiting | — | 15,000 | Technische Universität DresdenOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07541755 | PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL(PD1-VEN-CAG) | active not recruiting | Phase 3 | 40 | Fujian Medical University Union HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT05222984 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | active not recruiting | Phase 1 | 17 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05519579 | Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539610 | Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors | not yet recruiting | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | not yet recruiting | Phase 3 | 788 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT02390635 | PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04797767 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | recruiting | Phase 1 / Phase 2 | 62 | University of WashingtonOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06295965 | Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study | recruiting | — | 2,000 | University of WashingtonOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537257 | VEN+IDAC vs IDAC in AML | enrolling by invitation | Phase 2 / Phase 3 | 232 | Guangdong Second Provincial General HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537738 | Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia(MLL-LSC) | recruiting | — | 210 | Peking University People's HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 5, 2026source: clinicaltrials